Board summary
Key figures
70,575
Registered population
58.2% aged 18–64
20.5%
Aged 65+
ICB 19.9% · England 17.9%
6.5%
Ethnic minority (non-White)
3.1% Asian · England 9.6%
2.4%
In IMD quintile 1
ICB 17.1% · England 21.0%
~1,653
Core20 residents (est.)
Resident basis; registered basis ~1,729 · see page 3
11,205
Hypertension register
+6.75% in 3 yrs · England +5.60%
563
SMI register
53.6% of Tonbridge and Malling's
1,180
COPD register
Reviews -0.61% in 3 yrs
Forecast to 2030
13,743
Hypertension patients, 2030
+2,538 on today
71.8%
QRISK ≥20% on statins, 2030
+3.47pp over 3 yrs
6.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
CKD lipid therapy trails all comparators.
Lipid-lowering therapy in chronic kidney disease is 63.7%, below Tonbridge and Malling (66.3%), the ICB (69.2%) and England (70.3%), which may reflect recall gaps.
Wide practice gap in phone access.
Easy phone contact spans 54.5 pp across practices, from 34.4% at Woodlands Health Centre to 88.9% at Hadlow Medical Centre (England 56.9%).
Breast screening coverage exceeds national benchmark.
Breast screening coverage aged 53 to 70 is 77.3% (three-year change +14.4%), above the ICB (71.6%) and England (69.9%, +8.4%).
Population, age and ethnicity
Patients aged 65+ comprise 20.5% of the list alongside 10 catchment care homes
Across 70,575 registered patients, 20.5% (14,487) are aged 65+, exceeding Tonbridge and Malling (19.0%), the ICB (19.9%) and England (17.9%), alongside 10 catchment care homes (491 beds). Children aged 0–17 represent 21.3% (15,003), against 21.4% in the borough, 20.7% in the ICB and 19.6% in England. Resident Census ethnicity is 93.5% White (borough 93.2%, ICB 88.6%, England 81.1%) and 3.1% Asian (borough 2.9%, ICB 4.7%, England 9.6%). Census figures reflect usual residents rather than registered patients; projected 5.9% list growth to 2030 uses an unverified methodology.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Tonbridge and Malling local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Tonbridge and Malling LA) | 2,458 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.0% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.7% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Tonbridge and Malling LA) | 1,199 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Tonbridge and Malling LA) | 15.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 2.4% overall but spans 5.7 percentage points between member practices
Tonbridge PCN's average IMD decile is 7.1 (England 5.5; NHS Kent and Medway ICB 5.4), and Core20 share is 2.4% (England 21.0%). An estimated 1,653 residents live in deciles 1 and 2. Practice shares span 5.7 percentage points: Hildenborough Medical Group records 5.7% (estimated 950 patients) and Warders Medical Centre 2.5% (453 patients), whereas Woodlands Health Centre and Hadlow Medical Centre report 0.0%. Focusing outreach on practices with identified Core20 populations may help direct resources to deprived residents despite low PCN-wide prevalence.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
563
SMI register
0.80% recorded prevalence
354
Learning disability register
0.50% recorded prevalence
10
Care homes, 491 beds
In the PCN catchment
8.7%
Provide unpaid care
Tonbridge and Malling, Census 2021
Alongside 10 catchment care homes (491 beds), the PCN records 563 severe mental illness patients (0.8%, above the borough's 0.7%; 53.6% of borough cases) and 354 on its learning disability register. Tonbridge and Malling context shows an unpaid carer ceiling of about 6,100 and 6 rough sleepers in autumn 2025.
Severe mental illness: physical health checks
On the severe mental illness register, 80.7% have BMI recorded (England 82.1%), with three-year change of +1.9 pp (England +5.1 pp). Blood pressure recording change also trails England (+1.8 pp vs +4.4 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
11,205
Hypertension register
+6.75%
Register growth, 3 yrs
Tonbridge and Malling +6.16% · England +5.60%
−0.07pp
BP control, under 80
≤140/90 · +1.94pp aged 80+
+2,538
More patients by 2030
Forecast 13,743 (18.17%)
Hypertension case-finding and control
Tonbridge PCN records 11,205 patients on its hypertension register, representing a crude prevalence of 15.9%, above England (15.2%) and Tonbridge and Malling (15.5%) though below NHS Kent and Medway ICB (16.2%). Blood pressure monitoring reaches 90.9% of patients with hypertension (England 90.0%). For patients aged 80+, 81.5% have blood pressure at or below 150/90 mmHg (England 81.2%). However, blood pressure control for patients aged under 80 is 67.4%, trailing England (67.8%) with three-year change of -0.1% (England +3.2%). Tightening recall and titration for hypertensive patients aged under 80 addresses stalling control.
Lipids and statins
CKD lipid-lowering therapy reaches 63.7%, below England (70.3%), Tonbridge and Malling (66.3%) and NHS Kent and Medway ICB (69.2%). Primary-prevention diabetes statin therapy is 70.7% (England 73.2%). In 2026, lipid-regulating prescribing for patients aged 65+ was 9,257 items per 1,000 (England 18,056 rate). Fewer high-risk patients receive guideline lipid therapy than national rates imply.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 134,100 | £1.40 | £1.90 | £1.86 | £187,740 |
| Cardiovascular (all), 2025 | 183,595 | £2.47 | £3.57 | £3.33 | £453,480 |
In 2026, the PCN prescribed 134,100 lipid-regulating drug items at £1.40 per item (England £1.86, Tonbridge and Malling £1.57, NHS Kent and Medway ICB £1.90), spending £61,686 less than at England's unit cost across those 134,100 items. Lower unit costs relative to England reflect lower cost per item across prescribed volume.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+2.76%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.82%
Asthma prevalence, PCN 3-yr % change
The asthma register includes 4,378 patients (6.6% prevalence, matching England 6.6%), but 12-month reviews reach 57.0% (England 65.7%, NHS Kent and Medway ICB 60.4%), an unreviewed scale of about 1,900 patients. Second-hand smoke recording for ages 6–19 is 71.3% (England 78.8%). COPD prevalence is 1.7% (1,180 patients; England 1.9%), with reviews at 69.9% (England 76.4%) and three-year change of -0.6% (England +2.8%). Asthma prescribing for ages 5–19 is 1,143 items per 1,000 (England 1,488 rate).
Cancer register and children's immunisation
The cancer register records 3,517 patients (5.0% prevalence, above England 3.8%). In childhood immunisations, age-5 MMR dose 1 reaches 96.4% (above the 95.0% target), but dose 2 drops to 89.1% (a 7.3 pp gap; England 82.8%). The 4-in-1 booster reaches 86.7% (England 80.9%, target 95.0%). The dose-two drop-off indicates an opportunity to strengthen pre-school recall before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
The PCN cancer register holds 3,517 patients (5.0% prevalence; England 3.8%), following +11.8% 3-year growth (England +9.0%). Breast screening coverage is 77.3% (England 69.9%), rising +14.4% over three years (England +8.4%). Cervical screening (ages 25-49) fell 2.5% over three years to 72.5% (England -1.0%, ICB +0.5%). In wider-system data, NHS Kent and Medway ICB diagnosed 55.6% of staged cancers at stage 1 or 2 in 2022 (4,661 of 8,384; England 55.3%), 19.4 pp below the 75.0% national ambition by 2028, an annual ICB gap of 1,627 early-stage cases. Addressing screening drop-off could support earlier detection across eligible cohorts.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In wider-system metrics for July 2026 (provisional), Maidstone and Tunbridge Wells NHS Trust met the 62-day cancer referral to treatment standard at 87.4% (219 of 250.5 pathways), 2.4 pp above the 85.0% standard (ICB 75.9%, England 71.2%). The trust reached 81.8% on the 28-day faster diagnosis standard (target 75.0%) and 98.3% on 31-day combined treatment (target 96.0%). Provider waiting list shares at 6+ weeks were 0.5% for Computed Tomography, 0.9% for Magnetic Resonance Imaging, and 9.5% for Non-obstetric Ultrasound.
| Pathways within standard (%) | Maidstone and Tunbridge Wells | King's College | Dartford and Gravesham | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.78 | 80.68 | 78.14 | 76.78 | 79.32 |
| 31-day treatment (96%) | 98.35 | 96.68 | 97.48 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 87.43 | 70.15 | 63.59 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Maidstone and Tunbridge Wells | King's College | Dartford and Gravesham | England |
|---|---|---|---|---|
| MRI | 0.92 | 21.22 | 0.36 | 21.40 |
| CT | 0.51 | 22.60 | 2.08 | 9.92 |
| Echocardiography | 2.57 | 14.39 | 3.90 | 28.48 |
| Colonoscopy | 19.80 | 41.81 | 0.40 | 30.83 |
| Gastroscopy | 24.03 | 35.98 | 0.00 | 29.02 |
| All 15 DM01 tests | 6.42 | 19.15 | 8.37 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In June 2026 (provisional), community health service contacts for Tonbridge and Malling borough residents totalled 210,170. Of these, 138,250 contacts (65.8%) were with adults aged 65+. These activity totals capture all community provider activity delivered to borough residents rather than PCN-specific caseloads.
Practice variation and patient experience
Phone access varies by 54.5 percentage points across practices, alongside wide vaccination differences
Across member practices, 2025/26 overall QOF achievement ranges from 90.7% at Woodlands Health Centre to 96.8% at Warders Medical Centre (England 92.5%). Vaccination and immunisation achievement spans 49.8 percentage points (England 55.2%), from 22.4% at Woodlands Health Centre to 72.2% at Warders Medical Centre. Clinical domain achievement reached 96.9% at Hildenborough Medical Group and 100.0% at Hadlow Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Hadlow | 96 | 0.0 | 88.9% | 86.4% | 91.2% |
| Tonbridge Medical | 105 | 1.8 | 68.5% | 84.8% | 82.8% |
| Warders | 77 | 2.5 | 57.5% | 74.1% | 82.1% |
| Hildenborough | 117 | 5.7 | 44.8% | 71.7% | 77.9% |
| Woodlands | 101 | 0.0 | 34.4% | 65.7% | 69.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve of 25 measures trail England's three-year change, led by chronic reviews
Across 25 compared measures, 12 trail England's three-year change. The widest relative lags are heart failure reviews (+3.6% vs +8.7% in England), COPD reviews (-0.6% vs +2.8%), and under-80 blood pressure control (-0.1% vs +3.2%), alongside slower percentage-point gains in severe mental illness BMI recording (+1.9 pp vs +5.1 pp). Conversely, relative strengths include three-year gains in breast screening coverage (+14.4% vs +8.4%), diabetes statin therapy (+5.8% vs +2.1%), and HbA1c control (+6.3% vs +4.4%). Clinical review recall may require operational prioritisation across chronic condition registers.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
BP control, under 80
BMI record (SMI)
Hypertension treated to target
Breast screening (53-70)
Diabetes statin (no CVD)
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Tonbridge and Malling | Asset | PCN | Tonbridge and Malling |
|---|---|---|---|---|---|
| Care homes (catchment) | 10 (491 beds) | n/a | Schools (catchment) | 79 | n/a |
| Children's centres | 3 | 6 | Places of worship | 51 | 75 |
| Libraries | 3 | 7 | Food banks (VCS) | 1 | 1 |
| Homelessness support (VCS) | 1 | 1 | Day centres (VCS) | 1 | 4 |
| Children and young people (VCS) | 1 | no data | Carers support groups (VCS) | 1 | 2 |
| Primary schools (LA maintained) | 17 | 28 | Primary academies | 6 | 14 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and COPD review recall
Asthma reviews reach 57.0% of 4,378 patients (England 65.7%; 1,882 unreviewed scale). COPD reviews reach 69.9% of 1,180 (England 76.4%, -0.6% over 2023 to 2025 vs +2.8%). For discussion: practices could run a structured recall template for unreviewed asthma and COPD patients, pairing inhaler checks with flexible slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Under-80 hypertension and CKD lipid review
Under-80 BP control is 67.4% (England 67.8%; 2023 to 2025 change -0.1% vs +3.2%) on an 11,205 register. CKD lipid therapy is 63.7% (England 70.3%, ICB 69.2%). For discussion: the PCN could deploy pharmacist-led recall for hypertensive patients aged under 80 above 140/90 mmHg and untreated CKD patients. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
SMI health checks and Core20 outreach
Across 563 SMI patients (53.6% of borough), BMI recording is 80.7% (England 82.1%; +1.9 pp vs +5.1 pp) and BP rose +1.8 pp (England +4.4 pp). Core20 is 2.4% (England 21.0%). For discussion: practices could standardise single-visit SMI check templates and focus outreach on practices with Core20 populations. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Care home frailty coordination (p2) | Count of Care Homes in PCN catchment | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026 | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check protocol alignment (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Under-eighty blood pressure recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma and COPD review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Under-80 hypertension and CKD lipid review (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · SMI health checks and Core20 outreach (p12) | Severe mental illness register · SMI register with a BMI recorded in the last 12 months · Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
